NCT07519486 2026-04-15
INS-ESCC-CT
Sichuan University
Phase 2 Recruiting
Clinical Trials
6 trialsNCT07505186 2026-04-01
Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT05659251 2025-12-02
Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Active not recruiting
NCT06576973 2025-12-02
Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT07244978 2025-12-02
Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT04666090 2025-05-15
Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Active not recruiting